|

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

RECRUITINGSponsored by Fondazione Italiana Linfomi - ETS
Actively Recruiting
SponsorFondazione Italiana Linfomi - ETS
Started2024-05-07
Est. completion2027-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06070961

Summary

This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment undergoing frontline induction immuno-chemotherapy and anti-CD20 maintenance within the prospective FIL\_FOLL19 study (NCT05058404). Blood samples from patients will be collected before and at planned timepoints during treatment to evaluate humoral and cellular immunity against SARS-COV-2, VZV, tetanus and diphtheria and T-cell markers characterization.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Enrolment in FIL\_FOLL19 study
2. Previous vaccination for COVID-19 (at least 3 doses)
3. Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
4. Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
5. Signature of specific informed consent form

Exclusion Criteria:

None

Conditions3

CancerFollicular LymphomaLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.